Pearl River Capital, LLC Neurocrine Biosciences Inc Transaction History

Pearl River Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $525,407 - $687,562	-7,252 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $577,621 - $770,307	7,252 New	7,252 $618,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $159,144 - $223,673	-1,655 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$85.09 - $130.36 $288,455 - $441,920	-3,390 Reduced 67.2%	1,655 $202,000
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $437,906 - $598,185	5,045 New	5,045 $542,000
Q1 2019 May 02, 2019	SELL	$69.31 - $91.53 $13,862 - $18,306	-200 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$68.32 - $124.36 $13,663 - $24,872	200 New	200 $14,000

642

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.